These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 22891404)

  • 21. Golimumab.
    Mazumdar S; Greenwald D
    MAbs; 2009; 1(5):422-31. PubMed ID: 20065639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
    Hsia EC; Schluger N; Cush JJ; Chaisson RE; Matteson EL; Xu S; Beutler A; Doyle MK; Hsu B; Rahman MU
    Arthritis Rheum; 2012 Jul; 64(7):2068-77. PubMed ID: 22238071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Leu JH; Adedokun OJ; Gargano C; Hsia EC; Xu Z; Shankar G
    Rheumatology (Oxford); 2019 Mar; 58(3):441-446. PubMed ID: 30412238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry.
    Manara M; Caporali R; Favalli EG; Grosso V; Atzeni F; Sarzi Puttini P; Gorla R; Bazzani C; Fusaro E; Pellerito R; Rocchetta PA; Sinigaglia L
    Clin Exp Rheumatol; 2017; 35(5):804-809. PubMed ID: 28770712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
    Poddubnyy D; Rudwaleit M
    Expert Opin Drug Saf; 2011 Jul; 10(4):655-73. PubMed ID: 21554150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Golimumab, a fully human monoclonal antibody against TNFalpha.
    Hutas G
    Curr Opin Mol Ther; 2008 Aug; 10(4):393-406. PubMed ID: 18683105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Golimumab as the first monthly subcutaneous fully human anti-TNF-alpha antibody in the treatment of inflammatory arthropathies.
    Hutas G
    Immunotherapy; 2010 Jul; 2(4):453-60. PubMed ID: 20635999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biologics in Inflammatory and Immunomediated Arthritis.
    Luchetti MM; Benfaremo D; Gabrielli A
    Curr Pharm Biotechnol; 2017; 18(12):989-1007. PubMed ID: 29278210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany.
    Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
    Rheumatol Int; 2019 Jan; 39(1):131-140. PubMed ID: 30415451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
    Kremer J; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Han J; Taylor P
    Arthritis Rheum; 2010 Apr; 62(4):917-28. PubMed ID: 20131276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Furst DE; Kay J; Wasko MC; Keystone E; Kavanaugh A; Deodhar A; Murphy FT; Magnus JH; Hsia EC; Hsu B; Xu S; Rahman MU; Doyle MK
    Rheumatology (Oxford); 2013 Oct; 52(10):1845-55. PubMed ID: 23838027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dermatologic adverse events: golimumab, friend or foe?
    Zidi I; Bartegi A; Ben AN
    Pharmazie; 2011 Jan; 66(1):5-10. PubMed ID: 21391428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Golimumab: a tumor necrosis factor alpha inhibitor for the treatment of rheumatoid arthritis.
    McCluggage LK; Scholtz JM
    Ann Pharmacother; 2010 Jan; 44(1):135-44. PubMed ID: 20118145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides.
    Biggioggero M; Favalli EG
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S38-41. PubMed ID: 25381973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infliximab treatment for rheumatic disease: clinical and radiological efficacy.
    St Clair EW
    Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii67-9. PubMed ID: 12379627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M; Joseph GJ; Princic N; Harrison DJ
    J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
    Iannone F; Santo L; Anelli MG; Bucci R; Semeraro A; Quarta L; D'Onofrio F; Marsico A; Carlino G; Casilli O; Cacciapaglia F; Zuccaro C; Falappone PC; Cantatore FP; Muratore M; Lapadula G
    Semin Arthritis Rheum; 2017 Aug; 47(1):108-114. PubMed ID: 28216195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.
    Zhuang Y; Xu Z; Frederick B; de Vries DE; Ford JA; Keen M; Doyle MK; Petty KJ; Davis HM; Zhou H
    Clin Ther; 2012 Jan; 34(1):77-90. PubMed ID: 22169051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.